Pharma Thriller: ImClone’s Secret Suitor Remains Cloaked In Mystery
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly is rumored to be the admirer, offering $70 per share to outbid rival Bristol-Myers Squibb.
You may also be interested in...
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.
ImClone Tussles With Another Partner, Merck KGaA
Merck KGaA seeks more than $18 million in damages, alleging ImClone licensed rights to Erbitux patents it did not own.